Q4 2026 Poly Medicure Ltd Earnings Call Transcript
Key Points
- Poly Medicure Ltd (BOM:531768) is undergoing a strategic transition towards high-technology, high-complexity, high-growth segments, aiming to become a globally recognized brand in high-end medical devices.
- The company has successfully launched 35 new products across the group in FY26, including 20 products developed in-house.
- Poly Medicure Ltd (BOM:531768) has expanded its global footprint with the acquisition of Medyneo in Brazil, facilitating faster market entry due to existing regulatory licenses.
- The company reported a 12.3% growth in full-year consolidated revenue, with domestic business growing by 20% and international business by 9%.
- The company has maintained a strong balance sheet with consolidated cash reserves of around INR842 crores, earmarked for strategic initiatives.
- The company faced a challenging external environment, particularly impacting international revenue, resulting in only a 4% growth in stand-alone revenue.
- There are ongoing logistics challenges in West Asia, affecting the execution of pending orders due to shipping disruptions.
- The company is experiencing headwinds from increased raw material costs, particularly those linked to crude oil, impacting gross margins.
- The Renal segment faces competition from Chinese imports, which are benefiting from zero import duties under ASEAN agreements.
- The company's acquisitions, Citieffe and PendraCare, are currently operating at lower EBITDA margins, impacting consolidated profitability.
Ladies and gentlemen, good day, and welcome to the Poly Medicure Limited's Q4 FY26 earnings conference call. (Operator Instructions) Today on this call, we have with us from the senior management team of the company, represented by Mr. Himanshu Baid, the Managing Director; Mr. Naresh Vijayvergiya, CFO; Mr. Rahul Gautam, President, Strategy and Corporate Development.
I would now like to hand the conference over to Mr. Himanshu Baid. Thank you, and over to you, sir.
Thank you very much. Good evening, everyone. I welcome you all to our Q4 and full year FY26 earnings call. I sincerely thank you all for being here today. Last financial year, FY25-FY26 was a year of deliberate transition, deliberate transition, a fundamental upgrade from our business model towards high technology, high complexity, high-growth segments, a year in which we chose to invest in a difficult external environment rather than wait it out. We invested in high-technology verticals, build out clinical and R&D teams. And despite
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
